City of Hope has so many breakthroughs in cancer, diabetes and HIV/AIDS - and so many stories - that we've tailored our blog, Breakthroughs, to provide something for every reader. Whether the breakthroughs are about medical research, treatment advances or personal triumphs, they're all connected.
November 9, 2017 | By Katie Neith
City of Hope’s Defu Zeng, professor of diabetes immunology and hematopoietic cell transplantation and colleagues recently uncovered important information about the chronic GVHD.
April 18, 2017 | Katie Neith
An international team of researchers led by City of Hope’s Defu Zeng believe they may have found a way to prevent graft-versus host disease following stem cell transplants without sacrificing the transplants’ ability to fight leukemia and lymphoma.
January 12, 2016 | Letisia Marquez
Cheryl Taylor spent New Year’s Day in a brand new way. The City of Hope patient watched the Rose Parade from the grandstands, surrounded by strangers who quickly became friends after she told them she’s battled a rare, debilitating blood cancer – a myeloproliferative neoplasm – for almost 17 years.
November 20, 2015 | City of Hope
Graft-versus-host disease is a serious condition that affects many people who receive a bone marrow cell transplant. To better fight it, scientists need to better understand it. City of Hope researchers’ efforts to do just that recently got a $2.2 million boost from the National Institute of Allergy and Infectious Diseases, also known as NIAID.
February 20, 2015 | Kim Proescholdt
Each year, thousands of patients with hematologic malignancies undergo allogeneic stem cell transplantation (that is, they receive a donor's stem cells), offering them a chance at cure. Graft-versus-host disease is a potentially deadly complication of this therapy and occurs in approximately 25 to 60 percent of patients.
February 9, 2015 | Darrin Joy
Cancer patients face a daunting journey marked by challenges and uncertainties. For those undergoing bone marrow, or stem cell, transplantation, one complication poses a particular threat — chronic graft-versus-host disease (GVHD).